




HEALTH SERVICES 2018

Viridian Therapeutics Inc.\DE
Rank 31 of 65





RealRate

HEALTH SERVICES 2018

Viridian Therapeutics Inc.\DE Rank 31 of 65



The relative strengths and weaknesses of Viridian Therapeutics Inc.\DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viridian Therapeutics Inc.\DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 334% points. The greatest weakness of Viridian Therapeutics Inc.\DE is the variable Net Income, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 90%, being 106% points above the market average of -17%.

Input Variable	Value in 1000 USD
Assets, Current	51,868
Assets, Non-Current	50
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	10,912
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	3,897
Long Term Liabilities	10,074
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	383
Other Liabilities	0
Other Net Income	403
Other Revenues	4,003
Property Plant and Equipment	563
Research And Development Expense	19,623
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	52,481
Liabilities	13,971
Expenses	30,918
Revenues	4,003
Stockholders Equity	38,510
Net Income	-26,512
Comprehensive Net Income	-26,512
Economic Capital Ratio	90%